Dr. Mehdi Mirsaeidi is a highly skilled medical professional specializing in sarcoidosis, interstitial lung disease (ILD), and pulmonary infections. With extensive expertise in these areas, Dr. Mirsaeidi excels in diagnosing and treating complex cases while also conducting groundbreaking research. Passionate about advancing patient care and outcomes, he is committed to staying at the forefront of medical advancements and implementing novel approaches in his practice. Driven by a deep sense of compassion, Dr. Mirsaeidi strives to provide the highest level of care to his patients, leveraging his knowledge and experience to improve their quality of life. With a strong dedication to education, he also actively contributes to the training and mentorship of future medical professionals.
Areas of Expertise (4)
Interstitial Lung Disease
Complete Genome Sequencing of the Novel Pseudomonas aeruginosa Phage UF_RH1ASM Journals
Abdolrazagh Hashemi Shahraki, et. al
Here, we present the genome sequence of a novel Pseudomonas aeruginosa bacteriophage called UF_RH1. This lytic phage has a genome size of 42,567 bp and is classified as a member of the Siphoviridae family and the Septimatrevirus genus. UF_RH1 shares genetic similarities with Stenotrophomonas phage vB_SmaS-DLP_2. Pseudomonas aeruginosa is an opportunistic pathogen that poses significant challenges for treatment.
Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary SarcoidosisPulmonary Therapy
Mehdi Mirsaeidi, et. al
Introduction: Long-term treatment of pulmonary sarcoidosis with glucocorticoids has been associated with toxicity and other adverse events, highlighting the need for alternative therapies. The goal of this study was to evaluate the efficacy and safety of repository corticotropin injection (RCI, Acthar® Gel) in patients with pulmonary sarcoidosis and to validate endpoints for use in future clinical trials.
Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi studyERJ Open Research
Huda Asif, et. al
Rationale: Nontuberculous mycobacterial (NTM) diseases are difficult-to-treat infections, especially in lung transplant (LTx) candidates. Currently, there is a paucity of recommendations on the management of NTM infections in LTx, focusing on Mycobacterium avium complex (MAC), M. abscessus and M. kansasii.